Abnormalities in protein phosphorylation have been observed in numerous major human diseases,(1) strongly encouraging the search for pharmacological inhibitors of protein kinases.(2) The 2,6,9-trisubstituted purines were among the first low-molecular weight inhibitors of cyclin-dependent kinases (CDKs).(3) One of these, (R)-roscovitine, 10a (CYC202, Seliciclib), has now reached clinical phase 2 trials against nonsmall cell lung cancer and ...
![2-chloro-9-isopropyl-N-[[4-(2-pyridyl)phenyl]methyl]purin-6-amine Structure](https://image.chemsrc.com/caspic/148/294648-01-4.png)
